Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (June 2010)

31 slides from Paratek Pharmaceuticals's investor presentation, Jun 8, 2010

  1. Slide 1: A specialty pharmaceutical company focused on neuroscience

    Exhibit 99.1 A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience June 2010

  2. Slide 2: Forward looking statements

    Forward looking statements This slide deck contains forward-looking statements that are based upon current expectations within the meaning of the Private Securities Reform Act of 1995 and for which we intend that protection be gained by the safe harbor created thereby. Such statements involve risks

  3. Slide 3: Transcept Pharmaceuticals: company profile

    Transcept Pharmaceuticals: company profile Public listing through reverse merger in Jan 2009 – Nasdaq:TSPT Intermezzo® (zolpidem tartrate sublingual tablet): lead product candidate U.S. primary care partnership with Purdue Pharma, psychiatry co-promote option Strong balance sheet: $83.1M of cash, ca

  4. Slide 4: Transcept Pharmaceuticals: key corporate events

    Transcept Pharmaceuticals: key corporate events Intermezzo ®: Preclinical program and two Phase 3 studies completed: 2004-2008 Intermezzo ® NDA submitted: September 2008 U.S. commercial partnership: Purdue, Intermezzo ® primary care marketing and sales: July 2009 Intermezzo ® Complete Response Lette

  5. Slide 5: Intermezzo

    Intermezzo® Proposed indication statement: Intermezzo® (zolpidem tartrate sublingual tablet) is indicated for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep

  6. Slide 6: U.S. insomnia market

    U.S. insomnia market: ~76 M insomnia Rxs and ~5% Rx growth: March 2009-March 2010 Source: Wolters Kluwer Pharma Solutions 6

  7. Slide 7: Middle of the night awakening: #1 insomnia symptom

    Stanford Sleep Epidemiology Research Center: middle of the night awakening: #1 insomnia symptom Large scale population based sleep epidemiology study1, ~9,000 subjects over 4 years 35% report awakenings at least 3x per week >90% report awakenings persist more than six months Fewer than 25% of the mi

  8. Slide 8: Intermezzo: no product currently indicated for prn treatment of middle of the night awakening

    Intermezzo ®: no product currently indicated for prn treatment of middle of the night awakening Middle of the night awakenings typically did not occur every night, even in a more severely affected patient group ¹ Commonly prescribed 7 to 8 hour sleep aids require bedtime prophylactic dosing before a

  9. Slide 9: Intermezzo: anticipated to be the first sleep aid for use at the time of a middle of the night awakening

    Intermezzo ®: anticipated to be the first sleep aid for use at the time of a middle of the night awakening Sublingual tablet dissolves in ~ 2 minutes Novel formulation pH drives zolpidem base, rapidly absorbed Low dose 72% lower dose than Ambien CR®, the most commonly prescribed insomnia brand Fast

  10. Slide 10: Intermezzo 3.5 mg delivered greater early zolpidem bioavailability than a higher Ambien dose

    Intermezzo ® 3.5 mg delivered greater early zolpidem bioavailability than a ~3x higher Ambien ® dose

  11. Slide 11: Regulatory Review

    Regulatory Review PusaMArciTICAS ING

  12. Slide 12: FDA Complete Response Letter: October 2009

    FDA Complete Response Letter: October 2009 FDA indicated Transcept has submitted substantial evidence of effectiveness for the use of Intermezzo ® in its intended indication FDA recognized that the Intermezzo ® data did not indicate significant next-day residual effects at 4 hrs However, given the u

  13. Slide 13: Actions to address FDA Complete Response Letter

    Actions to address FDA Complete Response Letter Inadvertent re-dosing in a single night FDA has indicated that redesigned unit dose packaging appears to reduce the potential for inadvertent re-dosing in a single night. Inadvertent dosing with < 4 hours bedtime remaining FDA has agreed to a pre-appro

  14. Slide 14: Highway driving study overview

    Highway driving study overview Approximately 40 healthy adult volunteers Highway driving over a one-hour period Single-center (Maastricht), double-blind, randomized, placebo-controlled crossover design Key comparisons: – Intermezzo® 3.5mg vs. placebo, 4 hours post-dose – Intermezzo® 3.5mg vs. placeb

  15. Slide 15: U.S. Commercial Partnership: Purdue Pharma

    U.S. Commercial Partnership: Purdue Pharma

  16. Slide 16: Purdue Pharma: Intermezzo U.S. primary care marketing partner

    Purdue Pharma: Intermezzo ® U.S. primary care marketing partner > $2 billion 2008 revenue, leading pain therapeutic franchise, significant U.S. primary care marketing and sales presence Intermezzo ®: an important new product opportunity for Purdue Purdue team actively engaged with Transcept to addre

  17. Slide 17: Purdue Pharma agreement: key Transcept benefits

    Purdue Pharma agreement: key Transcept benefits Purdue to commercialize Intermezzo ® to U.S. primary care market Milestone payments – Upfront license fee: $25M received August 2009 – FDA approval milestone of $30M, reduced by $2M each 30-day period after June 30, 2010 – Up to $90M additional upon th

  18. Slide 18: Intermezzo: Intellectual property

    Intermezzo®: Intellectual property

  19. Slide 19: Intermezzo: two formulation patents issued; method of use patents pending

    Intermezzo ®: two formulation patents issued; method of use patents pending Formulation for transmucosal absorption – Two issued U.S. patents - 7,682,628 and 7,658,945 – Patents expire no sooner than February 2025 – Low dose zolpidem, ~1mg to ~5mg – Formulation with buffer system for transmucosal ab

  20. Slide 20: Pipeline development

    Transcept PHARMACEUTICALS, INC.

  21. Slide 21: TO-2061: low-dose ondansetron augmentation in TR-OCD

    TO-2061: low-dose ondansetron augmentation in treatment-resistant obsessive compulsive disorder (TR-OCD) Proposed indication statement: For use as an adjunctive therapy in adult patients with OCD who have not adequately responded to treatment with an SSRI 21

  22. Slide 22: Significant unmet medical need: Treatment Resistant OCD

    Significant unmet medical need: Treatment Resistant Obsessive Compulsive Disorder (TR-OCD) Obsessive Compulsive Disorder – Psychiatric disorder characterized by intrusive thoughts and repetitive actions that attempt to reduce the associated distress – 1% to 2% of U.S. population – Significantly inte

  23. Slide 23: Rationale for ondansetron augmentation in TR-OCD

    Rationale for ondansetron augmentation in TR-OCD Ondansetron: 5-HT3 antagonist (Zofran®) approved for chemotherapy-induced nausea and vomiting, typical daily doses of 16 mg to 24 mg Like SSRIs, ondansetron affects serotonin pathways and may enhance SSRI effects on OCD symptoms Like atypical antipsyc

  24. Slide 24: Two Transcept sponsored investigational studies of ondansetron augmentation in TR-OCD

    Two Transcept sponsored investigational studies of ondansetron augmentation in TR-OCD Pilot Study A: Ondansetron augmentation in patients who responded poorly to at least 12 weeks of SSRI treatment combined with an atypical antipsychotic, n=14 – Patients resistant to multiple treatments improved whe

  25. Slide 25: Ondansetron improved the symptoms in >50% of patients who responded poorly to SSRI treatment

    Ondansetron improved the symptoms in >50% of patients who responded poorly to SSRI treatment Pilot Study B: SSRI Augmentation Study n=21 0% 2.9% improvement at endpoint 10% 20% 30% 40% Responders (57% of patients) 44% Non-responders (43% of patients) improvement 50% at endpoint Week 2 Week 4 Week 6

  26. Slide 26: 8 of 12 responders relapsed within four weeks after ondansetron treatment period ended

    8 of 12 responders relapsed within four weeks after ondansetron treatment period ended Pilot Study B: SSRI Augmentation Study n=21 40 Ondansetron augmentation After ondansetron phase treatment period ended 30 38.3% worsening 20 from Week 12 10 Week Week Week Week Week Week Week Week Week 0 2 4 6 8 1

  27. Slide 27: Development overview: Low-dose ondansetron augmentation in TR-OCD

    Development overview: Low-dose ondansetron augmentation in TR-OCD Regulatory highlights – IND accepted Q2 2010: opening PK study may proceed – 505b2 NDA pathway PK studies: Planned for completion ~H1 2011 Phase 2, double-blind, placebo-controlled study of SSRI augmentation with low-dose ondansetron

  28. Slide 28: Financial Overview

    Financial Overview Transcept PHARMACEUTICALS, INC.

  29. Slide 29: Financial position: March 31, 2010

    Financial position: March 31, 2010 Cash & investments: $83.1 M Q1 2010 cash burn rate: $1.9 M / month Shares outstanding: 13.4 M Options / warrants / other: 2.5 Total: 15.9 M Employees: 31 29

  30. Slide 30: Key Transcept goals and activities

    Key Transcept goals and activities Completed Intermezzo ® US marketing partnership, July 09 Patent coverage: two Intermezzo ® formulation patents issued Proposal to FDA on Intermezzo ® NDA resubmission, Feb 10 FDA agreement on highway driving study design, March 10 Begin highway driving study, June

  31. Slide 31: Trademark notices

    Intermezzo ® is a registered trademark of Transcept Pharmaceuticals, Inc. Ambien ® is a registered trademark of sanofi-aventis Zofran ® and Paxil ® are registered trademarks of The GlaxoSmithKline Group of Companies Prozac ® is a registered trademark of Eli Lilly & Co. Luvox® and Luvox CR ® are regi

Transcept Pharmaceuticals — Investor Presentation (June 2010) on 6ix